Company intelligence / Profile preview

Somnus Therapeutics

Bedminster, New Jersey, United Statessomnusthera.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Phase 2 double-blind placebo-controlled crossover study completed to evaluate three doses of SKP‑1041, a new controlled-release formulation of zaleplon designed to activate 2–3 hours after ingestion to prevent mid-night awakenings in adults with primary insomnia. The trial aimed at determining optimal dosing and efficacy without next-day sedation effects. Results are not publicly detailed but trial completion indicates progression through Phase 2 successfully enough to report completion

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule therapeutics
Industry: Biotech

Drug pipeline

1 asset

SKP-1041

Partnerships

Licensed technology from SkyePharma PLC related to controlled-release formulation SKP‑1041

Beyond the preview

Go deeper on Somnus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Somnus Therapeutics.